Ayrmid Pharma and RoslinCT Announces Intent to Partner for Omisirge Manufacturing

• Ayrmid Pharma Ltd. and RoslinCT announced their intent to form a strategic partnership for the commercial production of Omisirge.

• The technology transfer and manufacturing are planned to take place at RoslinCT’s CGMP cell therapy facility in Hopkinton, MA.

Ayrmid Pharma Ltd., a cell therapy company developing cellular therapeutics, has announced its intent to partner with RoslinCT, a contract development and manufacturing organisation (CDMO), for the commercial production of Omisirge. Omisirge, a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy, was FDA-approved and launched in 2023 for the treatment of hematologic malignancies.

Under the intended agreement, RoslinCT will carry out the technology transfer and manufacturing of Omisirge at its CGMP cell therapy facility in Hopkinton, Massachusetts. The partnership aligns with Ayrmid Pharma’s global dual sourcing strategy to ensure a stable supply of Omisirge alongside its internal manufacturing capabilities.

Dr Joe Wiley, Chief Executive Officer of Ayrmid Pharma, stated, “As part of our global dual sourcing strategy, we are delighted to announce that we intend to work with RoslinCT on the technology transfer of Omisirge to their state-of-the-art facility in Hopkinton, MA. This key strategic move will allow Gamida Cell to source Omisirge for our patients from both our internal manufacturing capability and RoslinCT.”

Peter Coleman, Chief Executive Officer of RoslinCT, highlighted the collaboration’s significance, stating, “The dynamic interactions between the two teams are very productive, and we look forward to working with the Ayrmid Pharma Ltd. and Gamida Cell Inc. teams to support the production of this innovative product for their patients in the United States.”

The intended partnership reinforces RoslinCT’s role as a CDMO supporting commercial cell therapy products and strengthens Ayrmid Pharma’s supply chain strategy for Omisirge.